How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yassin-abdelghaffar-charity-center-for-liver-disease-and-research.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Yassin Abdelghaffar Charity Center for Liver Disease and Research — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yassin Abdelghaffar Charity Center for Liver Disease and Research pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Combined therapy LDV and SOF	Combined therapy LDV and SOF	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase	Virology / Hepatology
Combined Therapy SOF and DCV	Combined Therapy SOF and DCV	phase 3	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein	Virology / Hepatology

Therapeutic area mix

Virology / Hepatology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Ain Shams University · 1 shared drug class
Almaza Military Fever Hospital · 1 shared drug class
Egyptian Liver Hospital · 1 shared drug class
Federal University of São Paulo · 1 shared drug class
HaEmek Medical Center, Israel · 1 shared drug class
Hannover Medical School · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yassin Abdelghaffar Charity Center for Liver Disease and Research:

Cite this brief

Drug Landscape (2026). Yassin Abdelghaffar Charity Center for Liver Disease and Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yassin-abdelghaffar-charity-center-for-liver-disease-and-research. Accessed 2026-05-16.